Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Terns Pharmaceuticals, Inc. (TERN)

4.8   -0.33 (-6.43%) 09-27 16:00
Open: 5.13 Pre. Close: 5.13
High: 5.13 Low: 4.76
Volume: 541,970 Market Cap: 293(M)

Technical analysis

as of: 2023-09-27 4:22:28 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 6.31     One year: 6.77
Support: Support1: 4.76    Support2: 3.96
Resistance: Resistance1: 5.4    Resistance2: 5.8
Pivot: 5.2
Moving Average: MA(5): 5.1     MA(20): 5.23
MA(100): 8.29     MA(250): 8.54
MACD: MACD(12,26): -0.3     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 22.5     %D(3): 30.7
RSI: RSI(14): 32.2
52-week: High: 14.04  Low: 4.38
Average Vol(K): 3-Month: 603 (K)  10-Days: 635 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TERN ] has closed below the lower bollinger band by 9.9%. Bollinger Bands are 71.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.14 - 5.16 5.16 - 5.19
Low: 4.69 - 4.72 4.72 - 4.75
Close: 4.74 - 4.79 4.79 - 4.84

Company Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Headline News

Tue, 26 Sep 2023
Nonalcoholic Steatohepatitis (NASH) Market to Witness Growth by 2032, Estimates DelveInsight | Inventiva - Benzinga

Fri, 22 Sep 2023
Intriguing Block Trade Reveals Mysterious Financial Activity - Best Stocks

Sun, 10 Sep 2023
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating ... - MarketBeat

Wed, 06 Sep 2023
Terns Pharmaceuticals Reports Inducement Grants to New ... - GlobeNewswire

Thu, 17 Aug 2023
Terns Pharmaceuticals, Inc.: Gaining Momentum with Moderate Buy ... - Best Stocks

Wed, 09 Aug 2023
Terns Pharmaceuticals Inc Down 15.67% To $5.90 After Earnings Beat - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 61 (M)
Shares Float 38 (M)
% Held by Insiders 1.7 (%)
% Held by Institutions 102.4 (%)
Shares Short 4,780 (K)
Shares Short P.Month 4,390 (K)

Stock Financials

EPS -1.14
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.48
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -22.9
Return on Equity (ttm) -35.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.3
Qtrly Earnings Growth 0
Operating Cash Flow -52 (M)
Levered Free Cash Flow -27 (M)

Stock Valuations

PE Ratio -4.22
PEG Ratio 0
Price to Book value 1.06
Price to Sales 0
Price to Cash Flow -5.64

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.